Naturally Splendid USA To Explore Cannabigerol (CBGa) Biosynthesis

- March 9th, 2015

Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) announced that it is currently identifying multiple opportunities emerging from the recently acquired access to technologies from FSL Laboratories. According to CEO Craig Goodwin, “One of the opportunities in front of us is the potential to biosynthetically produce pharmaceutical grade cannabinoids without having to grow a single plant and thus potentially lowering the cost of production significantly, creating a competitive advantage over traditional extraction and formulation technologies.”

FSL Laboratories previously filed a patent application that covers the organic and enzymatic synthesis of cannabinoids. This technology has the potential for industrial scale production of cannabinoids catalyzed from Cannbigerolic acid (CBGa) without growing large quantities of plants, mimicing the natural synthesis that occurs in the plant.

Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) announced that it is currently identifying multiple opportunities emerging from the recently acquired access to technologies from FSL Laboratories. According to CEO Craig Goodwin, “One of the opportunities in front of us is the potential to biosynthetically produce pharmaceutical grade cannabinoids without having to grow a single plant and thus potentially lowering the cost of production significantly, creating a competitive advantage over traditional extraction and formulation technologies.”

FSL Laboratories previously filed a patent application that covers the organic and enzymatic synthesis of cannabinoids. This technology has the potential for industrial scale production of cannabinoids catalyzed from Cannbigerolic acid (CBGa) without growing large quantities of plants, mimicing the natural synthesis that occurs in the plant.

As quoted in the press release:

The Company is currently identifying multiple opportunities emerging from the recently acquired access to technologies from FSL Laboratories (FSL). Naturally Splendid CEO Craig Goodwin reports, “With the appointment of Mr. Racz as President of Naturally Splendid USA, we are now positioned to begin the process of monetizing the technologies we recently received from FSL. One of the opportunities in front of us is the potential to biosynthetically produce pharmaceutical grade cannabinoids without having to grow a single plant and thus potentially lowering the cost of production significantly, creating a competitive advantage over traditional extraction and formulation technologies This technology may be applied in the development of food, beverage and nutraceutical/cosmetic products and eventually for pharmaceutical applications”.

In this regards, the Company is pleased to report they have retained the services of Ms. Katie Schmitt, from Boreal Technologies. Ms. Schmitt will be directly involved in the transfer of technological expertise obtained under the agreement from FSL and implementation of commercialization strategies as the Company continues to progress with its plans to penetrate the evolving global opportunities. Naturally Splendid will license, develop, market and distribute cannabinoid products and technologies only in jurisdictions where these products are legal. The Company would like to emphasize that in accordance with regulatory direction provided by the TSX, the Company will obtain legal opinions of emerging business opportunities upon Exchange request.

Naturally Splendid VP of Operations Bryan Carson reports, “We are pleased to have Ms. Schmitt join the Naturally Splendid team as we process the multiple monetary opportunities surrounding our recent agreement with FSL. There is no better way to advance these opportunities than to retain key personal within Boreal to assist us in driving multiple revenue opportunities. This is further proof of the existing and in fact, the continued strengthening of the relationship between FSL / Boreal and Naturally Splendid”.

Ms. Schmitt reports, “FSL has filed a patent application covering the organic and enzymatic synthesis of cannabinoids. This technology will allow for industrial scale production of cannabinoids catalyzed from Cannbigerolic acid (CBGa) without the requirement to grow large quantities of plants. The process mimics the natural synthesis that occurs in the plant’s bio-pathway. Cannabinoids produced in the bioreactor are pharmaceutical grade purity (>99%) and devoid of by-products and impurities. The largest advantages with this technology over existing methods of cannabinoid production (natural and synthetic) are: its low price per unit manufacturing costs (potentially 1/10th to 1/3rd the cost of existing methods); its ability to produce a diversity of products from a single manufacturing line; and commercial scalability. It also creates access to lesser known cannabinoids for research and analysis of their potential therapeutic applications.

NSP will identify licensed partners in legal jurisdictions that it can collaborate with to develop safe and efficacious cannabinoid therapies utilizing this technology. Potential therapeutic applications include: Analgesic – Relieves pain; Antibacterial – Slows bacterial growth; Anti-inflammatory – Reduces inflammation systemically; and Anti-Proliferative – May Inhibit cancer cell growth through apoptosis.

Click here to read the Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) press release
Click here to see the Naturally Splendid (TSXV:NS,FWB:50N,OTCQB:NSPDF) profile.

Leave a Reply